NWBO OTC
Bethesda, MD 20814
US
Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BOYNTON ALTON L | G-Gift | 1,000,000 | $0.23 | 2024-08-29 |
| BOSCH MARNIX L | G-Gift | 3,000,000 | $0.35 | 2024-08-09 |
| BOYNTON ALTON L | G-Gift | 1,000,000 | $0.23 | 2024-08-08 |
| MALIK NAVID | S-Sale | 657,895 | $0.23 | 2024-07-26 |
| MALIK NAVID | S-Sale | 150,000 | $0.82 | 2023-11-17 |